Biomarkers Detect Atherosclerotic Plaques and
HealthCheck Diagnostics offers a new test that accurately predicts atherosclerosis and heart attacks. Doctors estimate up to 70% of people over 40 have coronary artery disease (CAD), but the disease is sub-clinical. There are no physical symptoms. Until now, there has been no non-invasive test to identify these CAD individuals.
HealthCheck Diagnostic draws on the immune response created by atherosclerotic disease. Tests use enzyme-linked immunosorbent assay (ELISA) plates coated with specific isotypes. The optical densities of antibody concentrations are determined based on a standard curve.
Get results in less than 24 hours.
Assays use patient blood serum diluted 1:1000 to check key biomarkers. The anti-MAA biomarkers nearly double between the control group and the atherosclerosis group with stable CAD This makes it easy to see who is in danger.
The level elevates about 50% higher when patients are in an acute myocardial infarction stage. Post heart attack, the levels drop slightly below the early CAD levels.
Elevations of responses tested by HeartDetect best show the antibodies that occur as an inflammatory response which is associated with atherosclerotic disease and clinical progression of chronic, stable coronary heart disease. This allows doctors to start preventive treatment.
Antibodies measured by AttackDetect come from the pathologic inflammatory response associated with active progressive or unstable CAD. They peak during a cardiac event, then drop considerably within 24 hours after the myocardial infarction following stabilization. This offers totally accurate determination of both the heart attack and its resolution.